Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
Clinical trial NCT07286942 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07286942
- Sponsor
- Jiangsu Cancer Institute & Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-18
- Primary completion
- 2027-12-18
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.